Roche Suspends Phase II Mircera Study In Chemo-Induced Anemia
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm halts recruitment of anemic non-small cell lung cancer patients due to an “imbalance” of deaths across study arms but maintains they are not related to the drug.
You may also be interested in...
Boxed Warning In Development For Procrit, Aranesp
Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.
Boxed Warning In Development For Procrit, Aranesp
Erythropoietin marketers J&J and Amgen will participate in an FDA Oncologic Drugs Advisory Committee meeting in May.
Amgen “Dear Doctor” Letter Warns Of Risk Of Death Associated With Aranesp
Letter follows release of data in patients receiving darbepoetin alfa who have anemia that is not due to concurrent chemotherapy, an off-label use.